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Abstract
Mesenchymal stem cells (MSCs) have acquired great interests for their potential use in the clinical therapy of many
diseases because of their functions including multiple lineage differentiation, low immunogenicity and
immunosuppression. Many studies suggest that MSCs are strongly immunosuppressive in vitro and in vivo. MSCs exert a
profound inhibitory effect on the proliferation of T cells, B cells, dendritic cells and natural killer cells. In addition, several
soluble factors have been reported to involved in the immunosuppressive effects by MSCs such as TGF-b,H G F ,P G E 2 ,
IDO and iNOS. These results suggest that MSCs can be used in the therapy of immune disorder diseases, prevention of
organ transplantation rejection and tissue injury. In recent study, we demonstrated that MSCs in tumor inflammatory
microenvironment might be elicited of immunosuppressive function. Thus, the application of MSCs in cancer therapy
might have negative effect by helping tumor cells escaping from the immune surveillance.
Keywords: Mesenchymal stem cells, Immunosuppression, Tumor growth
Introduction
Bone marrow is the most important source of adult stem
cells, which contains heterogeneous populations of cells
including hematopoietic stem cells, erythrocytes, fibro-
blasts, adipocytes and etc. Mesenchymal stem cells
(MSCs) is a subset of nonhematopoietic stem cells
existed in bone marrow originating from the mesodermal
germ layer[1,2]. MSCs were first identified by Frieden-
stein and were described as an adherent, fibroblast-like
population in the in vitro culture of bone marrow which
were also found to be able to differentiate into bone in
vivo[3]. MSCs also existed in other tissues, including adi-
pose, umbilical cord, fetal liver, muscle and lung [4-8].
MSCs have the ability to differentiate into multiple
lineages such as chondrocytes, osteocytes, adipocytes,
myocytes, and astrocytes, so MSCs could be considered
as a potential source of stem cells for cellular and
g e n e t i ct h e r a p y[ 5 , 9 ] .T h ep h e n o t y p eo fM S C si si d e n t i -
fied by the absence of the CD34 and CD45 hematopoie-
tic cell markers and is positive for CD29, CD90 and
CD105[10]. MSCs express the major histocompatibility
complex (MHC) class I but do not express MHC class
II, B7-1, B7-2, CD40 and CD40L molecules. MSCs can
be expanded more than 10
4-fold in culture without loss
of their multilineage differentiation potential. Some stu-
dies have established that bone-marrow-derived MSCs
can engraft injured tissues, such as those of the lung,
liver, heart, and brain, and recover their function. In
past ten years, many studies have confirmed that the
use of stem cell transplantation is an important tool in
the treatment of several types of malignancies[11-13].
For these reasons[14], such cells are currently being
tested for potential use in cell and gene therapy for
tumors[15,16]. In contrast, newer studies have proposed
that stem cells may be the direct cellular targets of the
genetic alterations that lead to tumor formation and
important contributors to the maintenance of human
cancers[17,18]. Emerging evidence suggests that both
bone-marrow-derived MSCs and mature stromal cells
can play an important role in the growth and develop-
ment of human malignancies[19,20].
The immunosuppressive properties of MSCs
In recent years, more and more researchers pay atten-
tion to the immune modulatory property of mesenchy-
mal stem cells and a large amount of researches have
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MSCs is the immunosuppressive properties. As immu-
nomodulators, MSCs may play important roles in many
diseases with immune disorder[21]. Accordingly, it is
very important to explore the molecular mechanisms of
immunosuppressive properties.
Mesenchymal stem cells and T cells
Several studies have demonstrated that MSCs can exert
immunosuppressive effect on T cells, which are a major
executor of the adaptive immune response. T cells
anergy induced by MSCs has been regarded as a poten-
tial mechanism of immune suppression. The prolifera-
tion of T cells induced by mitogens, alloantigens and
CD3 and CD28 antibodies is significantly inhibited by
MSCs [22-25].
MSCs lack surface expression of costimulatory mole-
cules, such as CD80 (B7-1) and CD86 (B7-2), and con-
stitutively express MHC-I while the expression of
MHC-II is relatively low or absent [22,26,27]. The inhi-
bition from MSCs affects several aspects associated with
the function of T cells including activation, antigen-spe-
cific proliferation, cytotoxic T cells (CTLs) formation,
down-regulation of IFNg in Th1 cells and up-regulation
of IL-4 in Th2 cells[24,28]. Potian et al [26] demon-
strated that MSCs could inhibit the cytotoxic effects of
antigen-primed CTLs and the internal mechanism is
due to suppression of the proliferation of CTLs, rather
than an inhibition of cytolytic activity[29,30].
It has been believed that soluble factors contribute to
MSCs immunesuppression because MSCs demonstrate
inhibition of PBMCs proliferation in a transwell system
[22,25,30]. However, conditioned culture medium col-
lected from MSCs does not illustrate inhibitory effect
unless they are cultured with lymphocytes indicating
that the production of immunesuppressive factors in
MSCs requires a cross-talk between MSCs and lympho-
cyte[26,31,32].
Several soluble factors are involved in MSCs-mediated
immunomodulation including transform growth factor-b
(TGF-b), hepatocyte growth factor (HGF), prostaglandin
E2 (PGE2), soluble HLA-G5, heme oxygenase (HO)-1,
indoleamine 2, 3-dioxygenase (IDO) and inducible
nitric-oxide synthase (iNOS)[33-36]. The soluble factors
are produced by MSCs constitutively or released after
MSCs cross-talk with target cells. It is important to
point out that the factors responsible for suppressing T
cells vary depending on the experimental system and in
vivo situations.
Furthermore, some studies describe the toll-like recep-
tors (TLRs), which are conserved family receptors that
recognize pathogen-associated molecular patterns and
promote the activation of immune cells, are involved in
the immune regulatory effects MSCs[37,38]. Pevsner-
Fischer et al. [38] demonstrated that expression of TLRs
molecules 1 to 8 is positive in MSCs and TLRs ligands
could effectively activate MSCs to produce IL-6 and
lead to NFB nuclear translocation. Nemeth et al. [39]
reported that MSCs activated by LPS or TNF-a could
reprogram macrophages by releasing PGE2. These
results suggest that TLRs and TNFR expression in
MSCs is associated with the immunosuppression.
Mesenchymal stem cells and B cells
Murine MSCs have been reported to have the inhibitory
effects on B cells in terms of proliferation, activation
and IgG secretion[40]. Furthermore, human MSCs could
also inhibit B cell proliferation. In addition, MSCs lead
to the downregulation of chemokine receptors CXCR4,
CXCR5 and CCR7 in B cells, which indicated that
MSCs could affect the chemotactic properties of B cells
[41]. The phenomenon that soluble factors released by
MSCs were sufficient to inhibit proliferation of B cells
in Transwell experiment while the culture supernatant
from MSCs had no effect, suggested that the production
of inhibitory soluble factors in MSCs needs paracrine
signals from B cells.
Mesenchymal stem cells and dendritic cells
D e n d r i t i cc e l l s( D C s )p l a yak e yr o l ei nt h ei n i t i a t i o no f
primary immune responses and in tolerance, depending
on the activation and maturation stage of DCs[42]. On
one hand, they contribute to activating naive T-cell dur-
ing the primary immune response. On the other hand,
they are also involved in activation of B cells by soluble
factors or Th cells. So DCs are extremely important not
only in cellular immunity but also in humoral immunity
[43].
Emerging evidence suggested that MSCs could inhibit
the activation and maturation of DCs. MSCs have been
reported to reduce the activation of T cells by reducing
the formation of DCs from monocytes [29]. MSCs could
inhibit the differentiation and function of DCs, as indi-
cated by transwell assay. Furthermore, the DCs which
were co-cultured with MSCs lost the potential to acti-
vate CD4+ T-cells in MLC[44]. MSCs can down-regu-
late the expression of CD40, CD1a, CD80, CD86 and
HLA-DR during the differentiation of monocytes to DCs
and suppress CD83 expression which associate with DCs
maturation [28,29,45,46].
MSCs are reported to reduce the production of several
cytokines in DCs, such as IL-12 and TNF-a.M S C s
decrease the function of DC to secrete IL-12, which is
important to promote an effective cellular immunity by
activating and differentiating T cells[45]. The decrease
of TNF-a secretion DC1 and increase of IL-10 in DC2
caused by MSCs may lead to a state of immune toler-
ance. IL-10, characterised by immunosuppression, can
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10-producing DCs lose their function to stimulate lym-
phocyte while effectively inhibited the proliferation of T-
cells[47-49]. PGE2 has also been observed to involve in
the modulation of DCs maturation. Blocking the pro-
duction of PGE2 in MSCs could delete their inhibitory
influence on DCs [50]. Djouad et al demonstrate that
high levels of IL-6 expressed by MSCs can lead to a
transformation of mature DCs to a less mature pheno-
type[51].
Mesenchymal stem cells and NK cells
Natural killer (NK) cells are major effector cells of the
innate immunity and play a key role in antiviral
responses[52]. NK cells mainly exhibit cytolytic activity
on the cells that lack expression of HLA class I mole-
cules. The killing function o fN Kc e l l si sc o n t r o l l e db y
the activating and inhibitory receptors interacting with
HLA molecules on target cells. The autologous cancer
cells are probably lysed by NK cells [53]. Several studies
have reported the interaction between MSCs and NK
cells [54-56]. It has been demonstrated that MSCs could
effectively inhibit IL-2-induced proliferation of resting
NK cells, whereas the proliferation of activated NK cells
is partially affected. Furthermore, IL-2-activated NK cells
(but not freshly isolated NK cells) efficiently lyse autolo-
gous and allogeneic MSCs [55]. The major receptors of
activating NK cells, NKp30, NKG2D and DNAM-1 play a
key role in NK cell-mediated cytotoxicity against MSCs.
The ligands of these activating NK receptors, ULBPs,
PVR and Nectin-2, are also expressed by MSCs.
Soluble factors such as TGF-b1, PGE2, and IDO may
play an important role in MSCs-mediated inhibition of
NK cells function [22,28,56,57]. The mechanisms under-
lying the immunosuppressive effects of MSCS are still
unclear. On one hand, Sotiropoulou et al [56] show that
PGE2 secreted by MSCs can partially affect NK cells
proliferation, CD56 expression and cytotoxicity without
interfering cytokine production or expression of activat-
ing receptors of NK cells. The proliferation of NK cells
is partially restored by inhibition of TGF-b1, while com-
bined blocking PGE2 and TGF-b1 will lead to a com-
plete recovery of NK cells proliferation. On the other
hand, Spaggiari et al [55] reported that MSCs could
effectively inhibit the proliferation of NK cells and the
simultaneous blocking of IDO and PGE2 could almost
completely restore NK-cell proliferation. Furthermore,
MSCs could markedly reduce killing ability of NK cells
on target cells [54].
Inflammatory microenvironment and immunosuppression
of MSCs
In the past, series of studies on MSCs immune modula-
tory properties were carried out in animal and human
with immune disorder disease[58,59]. Since the experi-
ment result that allogeneic MSCs are not rejected when
administered into baboon is achieved, the immune toler-
ance mechanism have been confirmed [60,61]. From lots
of in vivo studies, we know that MSCs can effectively
suppress immune response. But some contradictory
phenotype can be observed, which is an effective immu-
nosuppression can be achieved in some in vitro experi-
ments, but in vivo experiment MSCs injection do not
prolong allograft survival[62]. For instance, some studies
showed that MSCs cannot prolong graft survival in vivo
despite that they could suppress lymphocyte prolifera-
tion in vitro[63]. Some other studies also demonstrated
the similar results that MSCs could not prevent graft
rejection in vivo. To explain this phenomenon, we
detected the effects of mouse MSCs on T cells prolifera-
tion. The results indicate that indicate that there is no
difference in the proliferation of T cells blasts driven by
IL-2 with or without MSCs coculture[64,65] neither the
T cells hybridoma(A1.1). Therefore, we conclude that
MSCs do not suppress T cells proliferation without the
T cells activation. Based upon the above results, a ques-
tion was raised why immunosuppressive function of
MSCs is dependent on T cells activation.
To resolve this question, we culture MSCs with A1.1
cells or T cell blasts with the supplementation of super-
natant from anti-CD3-activated T cell cultures. The
result showed that T cell proliferation was significantly
inhibited, which suggested that some products of acti-
vated T cells played important roles in priming the
immunosuppression capacity of MSCs. Subsequent stu-
dies indicate that proinflammatory cytokines are needed
to induce the immunosuppression function of MSCs
such as IFN-g, TNF-a, IL-1a or IL-1b. IFN-g is essential
and TNF-a is the product of T cell. IL-1a and IL-1b
are the products of APCs [66]. Inflammatory cytokine
activated MSCs can inhibit the proliferation of many
types of immune cells, including freshly-isolated anti-
CD3-activated splenocytes, purified CD4+ T cells, CD8+
T cells or plastic-bound anti-CD3 activated T cell blasts,
anti-CD28, and LPS-activated purified B cells or macro-
phages. We also found that the activated MSCs can
inhibit the proliferation very efficiently as the ratio one
to 50 or 100 T cells. Therefore, the immune modulatory
properties of MSCs need the priming by inflammatory
cytokines. After making the above question clear, we
were drawn to another question which we cannot
explain. We found that T cells proliferation cannot be
suppressed when MSCs and T cells are cultured by
transwells or physical separation separately. Relevant
researches showed that the immunosuppressive effect of
mouse MSCs was completely diminished when inducible
nitric oxide synthase (iNOS) was inhibited by selective
inhibitors, NG-monomethyl-L-arginine (L-NMMA), N-
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(1400 W) or NG-Nitro-L-arginine Methyl Ester, Hydro-
chloride (L-NAME). In addition, MSCs derived from
mice deficient in iNOS did not inhibit T cells prolifera-
tion. Consequently, NO is an effector molecule in sup-
pressing immune reactions by inflammatory cytokine
-primed MSCs. Furthermore, NO can only affect the
cells near to it because of the biological activity
diminishes within a distance of a few cell diameter.
The role of MSCs in tissue injury repair and immune
disorder disease
Since they have immunosuppressive property, MSCs
were investigated as a new potential therapy for some
immune disorder diseases, such as graft-versus-host
disease (GvHD)[67,68], Crohn’s disease[69], and the
prevention of organ transplantation rejection[70].
Furthermore, many studies have demonstrated MSCs
play a critical role in injury healing [16,58,71-73].
MSCs transplantation is also regarded as a useful ther-
apeutic strategy in acute tissue injuries of the lung[74],
heart[75] and liver[76-78]. Although the lack of a reli-
able surface marker for MSCs hinder the identification
of MSCs that migrate to injury site, we still think it is
reasonable to suppose that MSCs may be mobilized
and recruit to a severe wound site[79]. On one hand,
MSCs may repair tissue injury by differentiation into
other kinds of cells; on the other hand, as a part of
microenvironment, MSCs support the growth of other
cells, such as fibroblasts, endothelial and epithelial
cells, macrophages, neutrophils and lymphocytes.
Our previous study has showed that IFN-g and NO pro-
duction were critical for immunosuppression of MSCs in
GvHD model[66]. MSCs can inhibit T cell response and
decrease inflammatory cytokines production in mouse
rheumatoid arthritis (RA) model[80]. In experimental
autoimmune encephalomyelitis (EAE), MSCs were also
observed to have a therapeutic effect on infiltration of T
cells in central nervous system (CNS)[23].
Role of MSCs immunosuppressive function in tumor growth
Chronic inflammation is associated with the whole pro-
cess of tumor occurrence and development. However,
immune response in the inflammatory environment of
tumor could suppress tumor growth. The contradictory
phenomenon brings us a problem which is how tumor
cells escaping from immune destruction in an inflamma-
tory microenvironment?(Figure 1)
MSCs play an important role in treating various
degenerative diseases and immune disorders. They have
great potential for correcting aberrant immune reac-
tions. Previous studies showed that these cells could be
expanded and induced ex vivo, terminally differentiate
into osteoblasts, chondrocytes, adipocytes, myotubes,
neural cells and hematopoietic supporting stroma
[5,9,81]. The immunosuppression demonstrated by
MSCs has been reported in several studies [22,24,36,82].
However, in certain circumstances the property of
immunosuppression may display negative effects such as
the promotion of tumor growth. Ren et al. have shown
that the immunosuppressive function of MSCs is elicited
by proinflammatory cytokines and the immunosuppres-
sion of MSCs is through the concerted action of chemo-
kines and NO[66]. MSCs have a tropism for tumors[83]
and the incidence and development of tumor is always
accompanied with proinflammatory cytokines. So it is
important to investigate the effect of MSCs favoring
tumor growth in inflammatory environment. To investi-
gate this hypothesis, we assessed the role of MSCs in
inflammatory environment on the development of
tumor by B16 melanoma cells implanted in allogeneic
mice. Our results suggest that the MSCs in tumor
inflammatory microenvironment may be elicited of
immunosuppressive function, which will help tumor to
escape from the immunity surveillance[84](Figure 2).
Recent studies have shown that MSCs displayed an abil-
ity to favor tumor growth under certain circumstance.
Djouad et al. [32] showed that MSCs had displayed side
effects related to systemic immunosupression favoring
tumor growth in vivo. Hall et al. [85] have also shown that
co-culture of ALL cell lines with stromal cells which is
overexpressed of VCAM-1 enhanced survival of leukemic
cells in a PI-3 kinase dependent manner, compared to the
Figure 1 Chronic inflammation associated with the whole
process of tumor occurrence and development. However, the
presence of immune response in inflammation is concerned as a
negative factor for tumor growth. The contradictory phenomenon
brings us a problem how tumor cells escape from immune
destruction in an inflammatory microenvironment?.
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V C A M - 1 .O nt h ec o n t r a r y ,M S C sh a v eb e e nr e p o r t e dt o
be anti-tumorigenic in a mouse model of Kaposi’ss a r c o m a
by inhibiting AKT activity [20]. Our study implies that
inflammatory cytokines may be the key factors that regu-
late the effect of MSCs on tumor growth. The presence of
an active immune reaction in tumor environment can lead
the MSCs that localized in tumor to acquire immunosup-
pressive function. On the other hand, the absence of active
inflammation in tumor may not only abstract MSCs to
localize but also induce them to be immunosuppressive.
Conclusions
Because of a wide range of MSCs function including
multiple lineage differentiation, low immunogenicity and
immunosuppression, have acquired many interests for
their potential use in therapy of many clinical diseases.
We can expect an exciting result for the application of
MSCs in some immune disorder diseases, prevention of
organ transplantation rejection and tissue injury. It
should be noted the study of MSCs clinical application
needs to pay attention to the local microenvironment.
Our results suggest that the MSCs in tumor inflamma-
tory microenvironment may be elicited of immunosup-
pressive function. Although MSCs have a tropism for
tumors and some studies reported to used MSCs as a
drug carrier for tumor therapy, the immunosuppression
of MSCs may be a risk to help tumor escaping from the
immunity surveillance. Therefore, the use of MSCs in
cancer therapy should be extremely cautious.
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